Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Virbac

Market Cap 2.87B 3.32B 2.64B 2.48B 4.64B 316B 4.71B 31.36B 12.18B 153B 12.47B 12.2B 532B P/E Ratio 2026 *
17.1x
P/E Ratio 2027 * 15.2x
Enterprise Value 2.99B 3.46B 2.75B 2.58B 4.83B 330B 4.91B 32.68B 12.7B 160B 12.99B 12.71B 554B EV / Sales 2026 *
1.93x
EV / Sales 2027 * 1.77x
Free-Float
49.03%
Yield 2026 *
0.51%
Yield 2027 * 0.6%
1 day+6.04%
1 month+6.04%
3 months-6.49%
6 months-6.49%
Current year-6.49%
1 month 408
Extreme 408
408
Current year 384.75
Extreme 384.75
408
1 year 384.75
Extreme 384.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 2025-08-31
Chief Executive Officer 50 2024-09-26
Chief Operating Officer 64 2021-12-31
Director TitleAgeSince
Chairman 61 2006-03-31
Director/Board Member 68 2010-07-27
Director/Board Member 65 2017-09-04
Change 5-day change 1-year change 3-year change Capi.($)
+6.04%-.--% - - 3.32B
+0.14%+4.91%-51.29%-50.09% 34.08B
+5.16%-2.12%+68.18%+165.45% 11.42B
-0.79%-7.64%+4.37%+28.88% 4.6B
-1.08%+3.47%+58.22%+19.30% 1.95B
+3.11%+6.62%-32.03%+1.36% 1.61B
+0.26%-1.67%+28.43%+131.56% 1.26B
-2.39%-5.75%-28.16%-12.83% 1.04B
-2.07%-2.07%-6.36%-44.56% 1.02B
-0.85%+4.32%-4.63%-21.41% 949M
Average +0.75%+0.24%+4.08%+24.18% 6.44B
Weighted average by Cap. +1.27%+1.38%-15.39%+7.65%

Financials

2026 *2027 *
Net sales 1.55B 1.79B 1.42B 1.33B 2.5B 170B 2.54B 16.9B 6.57B 82.67B 6.72B 6.57B 286B 1.64B 1.9B 1.51B 1.41B 2.65B 181B 2.69B 17.92B 6.96B 87.65B 7.12B 6.97B 304B
Net income 167M 193M 154M 144M 270M 18.41B 274M 1.83B 709M 8.93B 726M 710M 30.94B 190M 220M 175M 164M 307M 20.97B 312M 2.08B 808M 10.17B 826M 809M 35.24B
Net Debt 121M 140M 111M 104M 196M 13.34B 199M 1.32B 514M 6.47B 526M 514M 22.42B 26.49M 30.66M 24.37M 22.86M 42.83M 2.92B 43.51M 290M 112M 1.42B 115M 113M 4.91B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
342.50EUR
Average target price
412.88EUR
Spread / Average Target
+20.55%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!